![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 8
2021
Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Ladetto, M.; Tonino, S. H.; Herfarth, K.; Seymour, J. F. und Jerkeman, M.
(2021):
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 32, Nr. 3: S. 298-308
2017
Maddocks, K.; Gonzalez Barca, E.; Jurczak, W.; Liberati, A. M.; Duell, J.; Nagy, Z.; Papaj-K, T.; Andre, M.; Kalakonda, N.; Dreyling, M.; Zinzani, P. L.; Ambarkhane, S.; Weirather, J. und Salles, G.
(2017):
L-Mind: MOR208 Combined with Lenalidomide (Len) In Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R Dlbcl)-A Single-Arm Phase II Study.
In: Haematologica, Bd. 102: S. 174
Duell, J.; Gonzalez Barca, E.; Liberati, A. M.; Salles, G.; Gaidano, G.; Jurczak, W.; Nagy, Z.; Papajlk, T.; Andre, M.; Zinzani, P. L.; Kalakonda, N.; Ambarkhane, S.; Weirather, J.; Maddocks, K. und Dreyling, M.
(2017):
L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study.
In: Oncology Research and Treatment, Bd. 40: S. 68
Younes, A.; Hilden, P.; Coiffier, B.; Hagenbeek, A.; Salles, G.; Wilson, W.; Seymour, J. F.; Kelly, K.; Gribben, J.; Pfreunschuh, M.; Morschhauser, F.; Schoder, H.; Zelenetz, A. D.; Rademaker, J.; Advani, R.; Valente, N.; Fortpied, C.; Witzig, T. E.; Sehn, L. H.; Engert, A.; Fisher, R. I.; Zinzani, P.-L.; Federico, M.; Hutchings, M.; Bollard, C.; Trneny, M.; Elsayed, Y. A.; Tobinai, K.; Abramson, J. S.; Fowler, N.; Goy, A.; Smith, M.; Ansell, S.; Kuruvilla, J.; Dreyling, M.; Thieblemont, C.; Little, R. F.; Aurer, I.; Oers, M. H. J. van; Takeshita, K.; Gopal, A.; Rule, S.; Vos, S. de; Kloos, I.; Kaminski, M. S.; Meignan, M.; Schwartz, L. H.; Leonard, J. P.; Schuster, S. J. und Seshan, V. E.
(2017):
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
In: Annals of Oncology, Bd. 28, Nr. 7: S. 1436-1447
2016
Hermine, Olivier; Hoster, Eva; Walewski, J.; Bosly, A.; Stilgenbauer, S.; Thieblemont, C.; Szymczyk, Michal; Bouabdallah, R.; Kneba, M.; Hallek, M.; Salles, G.; Feugier, P.; Ribrag, Vincent; Birkmann, J.; Forstpointner, R.; Haioun, C.; Hänel, M.; Casasnovas, R. O.; Finke, J.; Peter, N.; Bouabdallah, K.; Sebban, C.; Fischer, T.; Dührsen, U.; Metzner, B.; Maschmeyer, G.; Kanz, L.; Schmidt, C.; Delarue, R.; Brousse, N.; Klapper, Wolfram; Macintyre, E.; Delfau-Larue, M. H.; Pott, Christiane; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2016):
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
In: Lancet, Bd. 388, Nr. 10044: S. 565-575
Dreyling, M.; Ghielmini, M.; Rule, S.; Salles, G.; Vitolo, U. und Ladetto, M.
(2016):
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
In: Annals of Oncology, Bd. 27:
v83-v90
2015
Delfau-Larue, M. H.; Klapper, Wolfram; Berger, F.; Jardin, F.; Briere, J.; Salles, G.; Casasnovas, O.; Feugier, P.; Haioun, C.; Ribrag, Vincent; Thieblemont, C.; Unterhalt, Michael; Dreyling, Martin; Macintyre, E.; Pott, Christiane; Hermine, Olivier und Hoster, Eva
(2015):
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
In: Blood, Bd. 126, Nr. 5: S. 604-611
Hoster, Eva; Geisler, C. H.; Doorduijn, J.; van der Holt, B.; Walewski, J.; Bloehdorn, J.; Ribrag, Vincent; Salles, G.; Hallek, M.; Pott, Christiane; Szymczyk, Michal; Kolstad, A.; Laurell, A.; Raty, R.; Jerkeman, M.; Van’t Veer, M.; Kluin-Nelemans, J. C.; Klapper, Wolfram; Unterhalt, Michael; Dreyling, Martin und Hermine, Olivier
(2015):
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
In: Leukemia, Bd. 30, Nr. 6: S. 1428-1430